Want to see JP:4512 full AI Analyst Report?

Wakamoto Pharmaceutical Co., Ltd. (4512) Price & Analysis

0 Followers

4512 Stock Chart & Stats

¥286.00

-¥4.00(-1.79%)

At close: Jan 08 4:00 PM EST

¥286.00

-¥4.00(-1.79%)

Day’s Range― - ―

52-Week Range¥240.00 - ¥380.00

Previous CloseN/A

Volume100.70K

Average Volume (3M)26.44K

Market Cap

¥10.38B

Enterprise Value¥7.82B

Total Cash (Recent Filing)¥3.56B

Total Debt (Recent Filing)¥100.00M

Price to Earnings (P/E)30.5

Beta0.37

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.16%

Share Statistics

EPS (TTM)-5.12

Shares Outstanding34,838,326

10 Day Avg. Volume25,590

30 Day Avg. Volume26,443

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)1.01

Price to Sales (P/S)1.23

P/FCF Ratio-11.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthStrong latest-year revenue growth indicates improved demand or commercial execution across the company’s businesses. If sustained, this expansion can broaden the revenue base, support operating leverage, and provide a foundation for stronger earnings over the next several quarters.

Gross Margin StabilityA consistently high-40% gross margin suggests the company retains reasonably stable product economics and some pricing or production advantages. This provides a foundation for converting future sales growth into profit, provided operating costs and other expenses remain controlled.

Low Financial LeverageVery low leverage materially reduces financial risk and limits the burden of interest or refinancing obligations. The substantial equity base also gives Wakamoto flexibility to withstand weaker periods and fund operations or opportunities without depending heavily on new borrowing.

Bears Say

Persistent Negative Cash FlowThree consecutive years of negative operating and free cash flow indicate that reported profitability has not translated reliably into cash. This can constrain internally funded investment, increase reliance on cash reserves, and make working-capital or investment demands more important to monitor.

Thin, Volatile ProfitabilityThin margins leave limited protection if demand weakens or costs rise, while the history of losses shows that earnings have not been consistently durable. Continued volatility could restrict reinvestment capacity and make future results more sensitive to execution and operating conditions.

Low Return On EquityPersistently low return on equity suggests the company is not yet converting its strong capital base into substantial shareholder returns. Unless profitability improves, excess equity may remain underutilized, limiting the efficiency and compounding potential of the business.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥240.00 and its highest was ¥380.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥10.38B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 13 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on Aug 05, 2026. The company reported ¥0.19 earnings per share for the quarter.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3.5 which represents an annual dividend yield of 1.16%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥0.19 in its last earnings report. Following the earnings report the stock price went up 2.23%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.